Dr. Wasserman is the Vice President, Cardiovascular and Metabolic Therapeutic Area Head and Head of the Development Design Center at Amgen. In these roles, he is responsible for the development and execution of the cardiovascular and metabolic strategy, including guiding product strategy, designing and conducting clinical trials, global registration of therapeutic candidates, and evaluation and in-licensing of external assets, and the optimization of clinical development programs across Amgen, respectively.
Since joining Amgen in June 2005, Scott has taken new therapies, including small and large molecules, from phase 1 through registration. He set strategy and executed critical global clinical programs in heart failure, anemia, osteoporosis, fracture healing, and lipid metabolism. He led cross-functional teams with representation from discovery, toxicology, clinical pharmacology, statistics, regulatory, safety, clinical operations, manufacturing, marketing, value and access, and medical affairs. As Amgen’s first cardiologist, Scott developed the company’s cardiovascular capabilities, shaped its cardiovascular portfolio, and built its Cardiovascular and Metabolic Therapeutic Area team. Over the last 5 years, Scott’s efforts focused on the design and execution of the global Repatha clinical trials program and registration. This program encompassed over 22 clinical trials with a combined planned enrollment of approximately 35,000 patients.
Prior to joining Amgen, Scott was on faculty at Stanford University in the Division of Cardiovascular Medicine. At Stanford, he performed NIH- and industry-funded research on flow-mediated endothelial gene expression and served as an invasive, non-interventional academic cardiologist with expertise in heart failure and echocardiography. He received his M.D., Magna Cum Laude from Harvard Medical School and his B.S., Magna Cum Laude from Haverford College. He completed his postgraduate training in Internal Medicine and Cardiovascular Medicine at Stanford University and did post-doctoral cardiovascular research at COR Therapeutics and Millennium Pharmaceuticals.